Aurinia Pharmaceuticals Inc (AUPH) Options

"I won't sell for less than "60.00"

Prove that you really missed me! I think you are not only FOS but also suffer from excrement of the 11th magnitude clogging what used to be your brain.

You might be the saddest and mentally sickest creature on the iHub boards.

I'm begging you to seek serious help ASAP.

I'm praying for you against the demons that clearly currently possess you.

.

keep up the great work pete, dang I miss all the posters that would exclaim "I won't sell for less than "60.00"
we can't even get 6.00 and you still love pete

Z. To correct the previous post where I mentioned VERA .
Their LN P 3 trial has been suspended
This suspension follows a previous setback with atacicept in lupus nephritis - the Phase II/III APRIL-LN trial evaluating atacicept in addition to mycophenolate mofetil was prematurely terminated due to unexpected declines in serum IgG levels and occurrence of serious infections in patients receiving atacicept.
It's worth noting that atacicept has shown more promising results in other conditions like IgA nephropathy, where it demonstrated an acceptable safety profile and improvements in proteinuria in the Phase II JANUS study. However, its development for lupus nephritis has faced challenges, with the COMPASS trial being the latest setback. The lack of safety concerns as the reason for suspension suggests there may be other factors at play, but without more information, the exact cause remains unclear.

So VERA's LN program is no longer a threat to AUPH.

Kiwi

Z. Is Lupkynis still a Tier 5 drug on formularies .
If so
For tier 5 drugs, which are typically specialty drugs, the copay structure is different from lower tiers. Instead of a fixed copay amount, you generally pay a percentage of the drug's cost, known as coinsurance.
According to the search results:
For most plans, you'll pay 25% to 33% of the retail cost for drugs in tier 5.
Tier 5 is often referred to as the "Specialty Tier" and includes unique and/or very high-cost drugs.
The coinsurance model means you pay a percentage of the total drug cost rather than a fixed copay amount.

Even if the patient makes it past the PA hurdles , they then need to deal with the copay
RMB posted the retail cost in a previous post ....how many " people of color "...or anyone else for that matter can pay 25-33% of the retail cost annually.

Other Co's like VERA also have LN drugs in clinical trials with promising data so far
https://veratx.com/science/atacicept-in-ln/

Good luck ... No position
Kiwi

Prior authorizations hurdles ...suggest you learn about them
Your source of information (your wife) gives you a very narrow perspective. I suggest you expand on your information gathering efforts.

I have personally seen VERY expensive drugs (Entyvio, $20K/month) go from very difficult to get (let all cheap drugs fail, patient suffer, long term damage, then more expensive treatment long term), and now, much easier to get as initial treatment.

I expect the same for Lupkynis, and I think we're getting very close to that point. As I said before, the fact that "communities of color" are disproportionally effected should also play some role!

See this from link:
Lupus nephritis is a serious chronic disease, one that has a disproportionately large impact on Black, Hispanic, and other communities of color in the US. Both belimumab and voclosporin are important new treatment options. Despite remaining uncertainty about both treatments’ longer-term outcomes, their estimated net prices appear to be aligned with their anticipated clinical benefits. More research is needed to confirm these benefits, but
for patients and clinicians to have responsibly priced options specifically indicated for lupus nephritis is a win for patients and the entire health system.

Meant to add this link from ICER:

https://icer.org/wp-content/uploads/2020/11/LN_RAAG.pdf

On the same track as what you are talking about, IIRC Aurinia’s margin on Lupkynis is astronomical so they would have room to decrease the price. I have thought that they didn’t want to decrease margins so as to appear more attractive to BP wrt a BO.

But a number of years have passed since approval and management has not been able to get more favorable insurance coverage nor has Aurinia been able to attract a suitor.

Whalatane- Thinking about what you are saying about the apparently prohibitively high (exorbitant) cost of Aurinia's Lupkynis, in your opinion/view is the following hypothetical scenario possible/feasible?

The price of Lupykynis gets cut to the same price as Benlysta (Belimumab), which I believe is essentially a garbage drug compared to voclosporin.
I'm thinking if that happened, the sales of Lupykynis would soar by multiples of what they are currently, since the performance of Benlysta is dramatically inferior.

TIA

It's my opinion based on the following knowledge .
Generally what happens is the insurance provider wants the patient to fail on all the less expensive options first . This requires a paper trail for the MD and patient and often both get fed up with the process and settle for what they can get and afford .
What the patient can afford is a key factor .
Brand drugs like Lupy are generally tier 5 on a formulary so the patient is responsible for a third of the cost of the script ....unless they have some special drug co plan or coupon .
Sometimes my wife will get approval for a fairly expensive drug for CKD patients ...write the script ...but when the patient is required to pay the copay at the pharmacy they decline to get the drug .

Kiwi

Kiwi is it your opinion or knowledge that PAs correlate with cost of the drug?

Just wondering if you know how difficult it is to get approval to use this drug .
So far my wife knows of it being used by only 2 patients in the SF area ...both at Stanford Ca .
Prior authorizations hurdles ...suggest you learn about them
Kiwi

to which pete responded "PFFF"

SEOUL, South Korea--(BUSINESS WIRE)--ILJIN SNT Co., Ltd. ("ILJIN"), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) ("Aurinia" or the "Company"), today issued an open letter to fellow shareholders. The full text of the letter is below.

=======================

July 11, 2024

Fellow Aurinia Shareholders,

Last month, Aurinia (“Company”) announced the voting results of its 2024 annual general meeting of shareholders (“AGM”). The Company announced that four directors -- (i) Peter Greenleaf, President and CEO and a Director, (ii) Daniel G. Billen, Director and Chair of the Board, (iii) R. Hector MacKay-Dunn, J.D, Director, and (iv) Brinda Balakrishnan, Director -- received less than the majority support required under the Company’s Majority Voting Policy.

No doubt the AGM results are a step in the right direction for the future of Aurinia. In this connection, we call on the Company’s Board to honor the voices of shareholders as expressed through the AGM, and accept the resignations of the four directors in accordance with the AGM voting results. We fully expect the Board will change as a result of this vote and begin to serve as a strong, effective board in ensuring improved management performance and securing a breakthrough in the Company stock’s performance in the near future.

So, after months of efforts, including issuance of the three public letters, ILJIN simply wanted to express our sincere gratitude to our fellow shareholders for having the courage to step up and finally making our voices heard. Our collective actions prove that no longer can entrenched management get away with massive losses on shareholders without a consequence to their compensation from the Company, and no longer may the Company’s management enrich themselves through the unrestrained grant of free RSUs -- irrespective of the Company’s performance.

Now, the AGM has paved the path for a change to the Company’s Board, we will need new directors who could help the Company forge a new strategic direction and successfully implement the strategic change. In this respect, we intend to maintain our vigilance and continue to press for the Board to listen to the constituent shareholders both in the selection of the composition of the Company’s new Board and adoption of a new growth strategy for Aurinia. We implore the Company to take the necessary changes at the Company to restore shareholder value in the nearest future possible.

Together, we will make a difference to the future of Aurinia.

Contacts
Media:
Yoonhwa Lee
yoonhwa.lee@iljin.co.kr

ILJIN SNT CO., LTD.

A few good quarters, some BO interest, and we're at $30 plus. It all depends on the long term profit potential.

$8-$10. No more

You thinking low double digits per share or not even that?

AUPH will be bought out before the year ends. It will not be at the price most longs here want. But it will be a fitting conclusion to this company.

Pete will right there ship. I guarantee it..

so the shareholders vote out some of the bod and yet we have not seen any letters of resignation.
just like when the supreme court tells biden he can't do something and jo gives them the finger and does it anyway.
you would thing if pete ad any integrity he would leave seeing how the vote showed no confidence in him to run the company other than run it in the ground as he has.

Jess, you too…

I don't think that matters anymore,

Was he native born?

dems looking for a crook to replace biden

petes on the short list

Looks like it

Probably just EOQ window dressing.

So surely not. Just jerking our chain.

Seems that volume Friday was almost 3x avg. Wonder if some developments are afoot?

Look in the mirror and say “you talkin to me”. You’re the one who yak a lot with the same narrative the last 24 months.

you yak a lot.
pete becomes more worthless each day to the company, all he has done is pilfer shareholder funds for his own personal gain
the company is worse off than when he was put in as ceo
stock price sits right where it did when he showed up
shareholders would have made more money in a 1/4percent savings account, some had bernie madoff we got stuck with a limp peter

The vote was for BoD only. The CEO is not elected, or voted out of office, by shareholders and never will be.

Your rant would be more persuasive if it was based on facts.

The CEO will be elected by the Board of Directors,…

His position as CEO was not up for a vote. His position as director was and he did not get a majority of votes to remain. Up to the BOD to can his ass

obviously rigged voting, no one with a living brain cell would have voted for pete to remain and destroy the company. i guess the more free shares they give themselves the more votes they can cast to keep stuffing money into their pockets.
I guess pete learned how to harvest votes from the dems

ho hum…

Agreed

so we will still be paying him 1.7 million a year to continue to do nothing?
what a waste of flesh

Greenleaf is out as a director, he still is CEO.

Hopefully the remaining BoD members got the message that investors, including enough institutional investors to carry the vote, believe that PG has failed and the compensation is excessive.

That should have been a given, so thankfully it happened.

Greenleaf is out!

It was all manipulation. Back to normal now

CRUSHED THIS MORNING

So that sounds like Iljin won’t be voting for PG. But my memory is poor - was it Iljin or MKT that saved his ass last year?

ILJIN: ‘Given the significant number of free shares involved, and vesting period running through 2027 we doubt whether Mr. Greenleaf had a genuine motivation to successfully conclude the Company's Strategic Review in 2023-2024.’

if you have ever seen a leech suck blood then you have seen pete

the only thing the bod and management
pete in particular are doing do position anything is lining their own pocketbooks with shareholder funds.
sales and patient numbers are not what I or any intellectual person would call "strong momentum"
now free shares over the years to petre and friends could easily be classified as "strong momentum" sucking the company dry.
quality management would cut management payroll in half until the company is truly profitable.
petes almost 2million salary plus millions in free shares each year is more criminal than bidens salary plus under the table deals for doing nothing but destroy the country.
are we sure pete really is not hunter?
pete is just blah blah blah same old with nothing to show for it other than a 29 dollar loss per share price.

Where you been Zzatty Boy. Over here screaming WE GOT ZZIENTISTS too. I see you’re saying the same gibberish over here that you did for a decade all while getting pummeled by 2 reverse splits. Buy in here at their peak too. LMAO

Interesting though that this was written in response to the Selce letter. Up until now the last thing we heard from the company was that they were stopping all drug programs. I don’t recall them ever talking about this since then.

That is great news Pablo!

The best news, if true, ((Advancing autoimmune pipeline with Phase 1 clinical program for AUR200,))

Dear Fellow Shareholders:

Aurinia’s Board of Directors and management team have been taking a range of actions to position the Company for sustainable success and build value for shareholders, while staying true to our core focus of delivering therapies to treat targeted patient populations with high unmet medical needs. We believe we have established strong momentum in the business based on recent actions to support our strategy in three key areas:

Focus on commercial execution after restructuring operations
Maximizing free cash flows, moving towards profitability, currently debt free with excess of $320M in cash, cash equivalents, restricted cash and investments
Advancing autoimmune pipeline with Phase 1 clinical program for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand)